CNTA

Centessa Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth 0/10
  • Momentum 7/10
Centessa Pharmaceuticals sales and earnings growth
CNTA Growth
Low
  • Revenue Y/Y 118.88%
  • EPS Y/Y -25.00%
  • FCF Y/Y -38.97%
Centessa Pharmaceuticals gross and profit margin trends
CNTA Profitability
Neutral
  • Gross margin 100.00%
  • EPS margin -1618.00%
  • ROIC -51.00%
Centessa Pharmaceuticals net debt vs free cash flow
CNTA Risk
Great
  • Debt / Equity 0.4
  • Debt / FCF 0.4
  • Interest coverage -20.5

Centessa Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗